Indegene Limited has announced a strategic acquisition that solidifies its growing commitment to the life sciences consulting market.
The company confirmed that its wholly owned subsidiary, Indegene Ireland Limited, signed a Share Purchase Agreement (SPA) on October 16, 2025, to acquire 100% of the equity shares in Warn And Co Limited.
This acquisition is strategically focused on further augmenting Indegene’s capabilities and offerings in the life sciences consulting business.
Warn And Co Limited is a UK-based entity incorporated on May 10, 2013. It specialises in providing business transformation consulting solutions tailored for its Lifes Sciences clients.
Specifically, Warn provides transformational consulting solutions that cover change management, organisation design, and solution design across the UK region.
The target company operates within the broader Business Consulting industry.
The transaction terms indicate that Indegene will acquire 100% control of Warn. The acquisition is structured as an all-cash transaction, with the total purchase consideration not exceeding GBP 3 million.
This amount is subject to customary net working capital adjustments and includes deferred performance/milestone-based consideration.
Financially, Warn And Co reported an unaudited revenue of GBP 2.5 million in its last financial year, covering the period from May 1, 2024, to April 30, 2025.
The Target Company has demonstrated relatively consistent turnover in recent years, reporting unaudited turnover of GBP 2.5 million in FY23 (a 14-month period) and GBP 2.0 million in FY24.
Indegene confirmed that the deal is not classified as a related party transaction, and there is no interest held by any promoter, promoter group, or group companies in the entity being acquired.
The acquisition is anticipated to be completed rapidly, with the indicative time period for completion set as on or before October 17, 2025. The deal also did not require any governmental or regulatory approvals
Signed: Srishti Ramesh Kaushik, Company Secretary and Compliance Officer, for Indegene Limited.
Disclosure: This information was provided pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Disclaimer: The information provided is for educational purposes only and does not constitute financial advice. We are not registered financial advisors. Please conduct your own research and consult a qualified advisor before making investment decisions. Any investment decisions you make based on this information are solely at your own risk.
